Clinical trials: Uncomplicated Plasmodium Falciparum Malaria, open to volunteers
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria
Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria
- Trial name
- PLATINUM (NCT05750628)
- Testing
- INE963, KAE609 (Cipargamin), SoC (Coartem)
- Where
- 12 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 327 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated Malaria
This study is being conducted to further evaluate the safety and clinical outcomes of Coartem® Baby (artemether/lumefantrine 5 mg/60 mg) in neonates and infants weighing ≥2 kg to <5 kg with uncomplicated malaria due to Plasmodium…
- Trial name
- NCT07713602
- Testing
- Coartem® Baby
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Malaria (Plasmodium Falciparum)
Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria
This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL).
- Trial name
- NCT07559370
- Testing
- Artemether lumefantrine tablets, Artemether Lumefantrine and Imatinib Mesylate
- Where
- Kenya
- Volunteers
- 1,116 people
- Sponsor
- Victoria Biomedical Research Institute
Uncomplicated Plasmodium Falciparum Malaria
A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines
The goal of this open-label randomised, controlled, non-inferiority trial is to assess and compare the efficacy, tolerability and safety of a fixed dose TACT artemether-lumefantrine-amodiaquine (ALAQ) to the ACTs…
- Trial name
- FD-TACT (NCT05951595)
- Testing
- Artemether-Lumefantrine-Amodiaquine (ALAQ), Artemether-Lumefantrine (AL), Artesunate-Amodiaquine (ASAQ)
- Where
- Rwanda
- Volunteers
- 1,680 people
- Sponsor
- University of Oxford
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)
This was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07811908)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 13 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Malaria, Falciparum
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria
The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.
- Trial name
- NCT07545681
- Testing
- GSK3772701 600 mg, GSK3772701 900 mg, GSK3772701 150 mg
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Plasmodium Vivax Malaria Without Complication, Plasmodium Falciparum Malaria (Uncomplicated)
Ethiopian Antimalarial Therapeutic Efficacy Study 2026
Background: The WHO recommends monitoring the efficacy of antimalarial drugs at least once every two years after implementation.
- Trial name
- TES2026 (NCT07840898)
- Testing
- Artemether-Lumefantrine + Primaquine and Chloroquine + Primaquine
- Where
- Ethiopia
- Volunteers
- 1,200 people
- Sponsor
- Ethiopian Public Health Institute